ATE237613T1 - Verfahren für die herstellung von antiviralen substituierten 1, 3-oxathiolanen - Google Patents
Verfahren für die herstellung von antiviralen substituierten 1, 3-oxathiolanenInfo
- Publication number
- ATE237613T1 ATE237613T1 AT93900063T AT93900063T ATE237613T1 AT E237613 T1 ATE237613 T1 AT E237613T1 AT 93900063 T AT93900063 T AT 93900063T AT 93900063 T AT93900063 T AT 93900063T AT E237613 T1 ATE237613 T1 AT E237613T1
- Authority
- AT
- Austria
- Prior art keywords
- oxathiolanes
- production
- antiviral
- substituted
- antiviral substituted
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 abstract 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
- C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
- C07D327/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/308,101 US5047407A (en) | 1989-02-08 | 1989-02-08 | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
| US56416090A | 1990-08-07 | 1990-08-07 | |
| CA002152269A CA2152269C (en) | 1989-02-08 | 1992-12-21 | Process for preparing substituted 1,3-oxathiolanes with antiviral properties |
| PCT/CA1992/000557 WO1994014802A1 (en) | 1989-02-08 | 1992-12-21 | Process for preparing substituted 1,3-oxathiolanes with antiviral properties |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE237613T1 true ATE237613T1 (de) | 2003-05-15 |
Family
ID=27170036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT93900063T ATE237613T1 (de) | 1989-02-08 | 1992-12-21 | Verfahren für die herstellung von antiviralen substituierten 1, 3-oxathiolanen |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0674634B1 (de) |
| JP (1) | JP3160291B2 (de) |
| AT (1) | ATE237613T1 (de) |
| AU (1) | AU3154993A (de) |
| CA (1) | CA2152269C (de) |
| DE (1) | DE69233014T2 (de) |
| DK (1) | DK0674634T3 (de) |
| ES (1) | ES2196004T3 (de) |
| HU (1) | HU226137B1 (de) |
| PT (1) | PT674634E (de) |
| WO (1) | WO1994014802A1 (de) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6175008B1 (en) * | 1988-04-11 | 2001-01-16 | Biochem Pharma Inc. | Processes for preparing substituted 1,3-oxathiolanes with antiviral properties |
| US5914331A (en) * | 1990-02-01 | 1999-06-22 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
| US5204466A (en) * | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
| US5827727A (en) | 1990-02-01 | 1998-10-27 | Emory University | Method of resolution of 1,3-oxathiolane nucleoside enantiomers |
| US5276151A (en) * | 1990-02-01 | 1994-01-04 | Emory University | Method of synthesis of 1,3-dioxolane nucleosides |
| US5444063A (en) * | 1990-12-05 | 1995-08-22 | Emory University | Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity |
| GB9116601D0 (en) * | 1991-08-01 | 1991-09-18 | Iaf Biochem Int | 1,3-oxathiolane nucleoside analogues |
| CA2637774C (en) | 1993-09-10 | 2011-07-19 | Emory University | Nucleosides with anti-hepatitis b virus activity |
| US20020120130A1 (en) | 1993-09-10 | 2002-08-29 | Gilles Gosselin | 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents |
| US5587362A (en) * | 1994-01-28 | 1996-12-24 | Univ. Of Ga Research Foundation | L-nucleosides |
| IL113432A (en) * | 1994-04-23 | 2000-11-21 | Glaxo Group Ltd | Process for the diastereoselective synthesis of nucleoside analogues |
| US6391859B1 (en) | 1995-01-27 | 2002-05-21 | Emory University | [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides |
| US5703058A (en) | 1995-01-27 | 1997-12-30 | Emory University | Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent |
| US5808040A (en) * | 1995-01-30 | 1998-09-15 | Yale University | L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides |
| ATE346651T1 (de) | 1995-06-07 | 2006-12-15 | Univ Emory | Nucleoside mit anti-hepatitis b virus wirksamkeit |
| US5753789A (en) * | 1996-07-26 | 1998-05-19 | Yale University | Oligonucleotides containing L-nucleosides |
| IT1290447B1 (it) * | 1997-03-28 | 1998-12-03 | Zambon Spa | Derivati 1,3-ossatiolanici ad attivita' antivirale |
| WO1998044913A2 (en) | 1997-04-07 | 1998-10-15 | Triangle Pharmaceuticals, Inc. | Compositions containing mkc-442 in combination with other antiviral agents |
| DK1140937T3 (da) | 1998-12-23 | 2004-03-22 | Shire Biochem Inc | Antivirale nucleosid-analoger |
| WO2003051298A2 (en) * | 2001-12-14 | 2003-06-26 | Pharmasset Ltd. | Preparation of intermediates useful in the synthesis of antiviral nucleosides |
| DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
| DE10238722A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
| WO2009069011A1 (en) | 2007-11-29 | 2009-06-04 | Ranbaxy Laboratories Limited | Process for the preparation of substituted 1,3-oxathiolanes |
| JP5498392B2 (ja) | 2007-11-30 | 2014-05-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | １，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用 |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| CN102143965A (zh) | 2008-09-08 | 2011-08-03 | 贝林格尔.英格海姆国际有限公司 | 吡唑并嘧啶酮及其在治疗中枢神经系统疾病中的用途 |
| PT2414363E (pt) | 2009-03-31 | 2014-02-26 | Boehringer Ingelheim Int | Derivados de 1-heterociclil-1,5-di-hidro-pirazolo[3,4- d]pirimidin-4-ona e sua utilização como moduladores de pde9a |
| UA110347C2 (uk) | 2010-08-12 | 2015-12-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | ПОХІДНІ 6-ЦИКЛОАЛКІЛ-1,5-ДИГІДРОПІРАЗОЛО[3,4-d]ПІРИМІДИН-4-ОНУ І ЇХ ЗАСТОСУВАННЯ ЯК ІНГІБІТОРІВ PDE9A |
| US8809345B2 (en) | 2011-02-15 | 2014-08-19 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders |
| CN104059057A (zh) * | 2014-01-03 | 2014-09-24 | 石家庄龙泽制药有限公司 | 拉米夫定杂质3-tu的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5047407A (en) * | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
| US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
| GB9009861D0 (en) * | 1990-05-02 | 1990-06-27 | Glaxo Group Ltd | Chemical compounds |
| AU8864191A (en) * | 1990-11-13 | 1992-06-11 | Biochem Pharma Inc. | Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties |
| AU9125991A (en) * | 1990-12-05 | 1992-07-08 | University Of Georgia Research Foundation, Inc., The | Enantiomerically pure beta -l-(-)-1,3-oxathiolane nucleosides |
| IL100965A (en) * | 1991-02-22 | 1999-12-31 | Univ Emory | 2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it |
| CA2105486C (en) * | 1991-03-06 | 2003-10-28 | George Robert Painter Iii | Therapeutic nucleosides |
| WO1992018517A1 (en) * | 1991-04-17 | 1992-10-29 | Yale University | Method of treating or preventing hepatitis b virus |
| ZA923641B (en) * | 1991-05-21 | 1993-02-24 | Iaf Biochem Int | Processes for the diastereoselective synthesis of nucleosides |
-
1992
- 1992-12-21 ES ES93900063T patent/ES2196004T3/es not_active Expired - Lifetime
- 1992-12-21 CA CA002152269A patent/CA2152269C/en not_active Expired - Fee Related
- 1992-12-21 AU AU31549/93A patent/AU3154993A/en not_active Abandoned
- 1992-12-21 DE DE69233014T patent/DE69233014T2/de not_active Expired - Fee Related
- 1992-12-21 PT PT93900063T patent/PT674634E/pt unknown
- 1992-12-21 AT AT93900063T patent/ATE237613T1/de not_active IP Right Cessation
- 1992-12-21 HU HU9501825A patent/HU226137B1/hu not_active IP Right Cessation
- 1992-12-21 DK DK93900063T patent/DK0674634T3/da active
- 1992-12-21 EP EP93900063A patent/EP0674634B1/de not_active Expired - Lifetime
- 1992-12-21 WO PCT/CA1992/000557 patent/WO1994014802A1/en not_active Ceased
- 1992-12-21 JP JP51462194A patent/JP3160291B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO1994014802A1 (en) | 1994-07-07 |
| HUT73655A (en) | 1996-09-30 |
| JP3160291B2 (ja) | 2001-04-25 |
| DK0674634T3 (da) | 2003-08-04 |
| EP0674634B1 (de) | 2003-04-16 |
| JPH08504212A (ja) | 1996-05-07 |
| HU9501825D0 (en) | 1995-08-28 |
| PT674634E (pt) | 2003-09-30 |
| CA2152269A1 (en) | 1994-07-07 |
| CA2152269C (en) | 1999-09-21 |
| DE69233014D1 (de) | 2003-05-22 |
| ES2196004T3 (es) | 2003-12-16 |
| DE69233014T2 (de) | 2004-01-08 |
| AU3154993A (en) | 1994-07-19 |
| HU226137B1 (en) | 2008-05-28 |
| EP0674634A1 (de) | 1995-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69233014D1 (de) | Verfahren für die herstellung von antiviralen substituierten 1, 3-oxathiolanen | |
| ES2091948T3 (es) | 1,3-oxatiolanos sustituidos con propiedades antiviricas. | |
| ATE44954T1 (de) | Carbostyrilderivat und verfahren zu seiner herstellung. | |
| ATE136315T1 (de) | Verfahren für die herstellung von polyethylenglykolderivate und modifizierte proteine. | |
| AT380252B (de) | Verfahren zur herstellung von neuen guanin- und 2,6-diaminopurinderivaten und ihren salzen | |
| ES2091212T3 (es) | Compuestos de xantina. | |
| ATE158798T1 (de) | Verfahren zur herstellung von optisch aktiven zyklobutannukleosiden | |
| DE69108014D1 (de) | Verfahren zur herstellung von nucleosiden und ihre analogen. | |
| ATE57703T1 (de) | Verfahren zur herstellung von 2,6-substituierten 9-(1,3-dihydroxy-2-propoxymethyl)-purinen und einige derivate. | |
| ES545194A0 (es) | Un procedimiento para preparar derivados de purina | |
| ATE130845T1 (de) | Verfahren zur herstellung von 3-amino-2- (het)aroyl-acrylsäurederivaten. | |
| DE59005334D1 (de) | Verfahren zur Herstellung von reinem Guanin. | |
| FI890678A0 (fi) | Analogiamenetelmä terapeuttisesti käyttökelpoisten 1,3-dioksaanialkeenihappojohdannaisten valmistamiseksi | |
| ATE132863T1 (de) | Verfahren zur herstellung von 6-(substituiertes aminopropionyl)-derivaten von forskolin | |
| IT8548429A0 (it) | Composizione a base di esteri parziali dell'acido fosforico,impiegabili per l'ingrasso in mezzo acquoso delle pelli conciate | |
| ATA143787A (de) | Verfahren zur herstellung von neuen derivaten der 4-phenyl 4-oxo 2-butensaeure | |
| ATE147075T1 (de) | Purinverbindungen, verfahren zu ihrer herstellung, pharmazeutische präparate und zwischenverbindungen | |
| DE68904680D1 (de) | Carbamatderivate und verfahren zu ihrer herstellung. | |
| ATE128357T1 (de) | Ophthalmikum. | |
| DE3667464D1 (de) | Verfahren zur herstellung von 2-acyl-3,4-dialkoxyanilinen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0674634 Country of ref document: EP |
|
| EEFA | Change of the company name | ||
| EEFA | Change of the company name | ||
| REN | Ceased due to non-payment of the annual fee |